

*A*  
*Conc'd*

238. (New) The pharmaceutical composition of any one of claims 192-231, wherein the compound is in the form of a dosage unit.

239. (New) The pharmaceutical composition of claim 238, wherein the dosage unit contains 10 to 1500 mg of the compound.

240. (New) The pharmaceutical composition of claim 239, wherein the dosage unit is a tablet or capsule.

241. (New) The pharmaceutical composition of claim 238, wherein the dosage unit is a tablet or capsule.

### Remarks

Original claims 156 and 163, and new claims 175-241 are pending, and are directed to 3'-substituted pyrimidine nucleoside compounds, and pharmaceutical compositions including such compounds. New claims 175-191 are directed to  $\beta$ -L-2'-deoxy-3'-substituted cytidines. Support for these claims can be found on page 13, line 16 to page 14, line 26 of the specification. New claims 210-231 are directed to pharmaceutical compositions including  $\beta$ -L-2'-deoxy-3'-substituted cytidines in combination with one or more anti-hepatitis B virus agent. Support for these claims can be found on page 17, lines 3-12 and page 45 line 7 to page 47, line 19 of the specification. Claims 192-241 are directed to pharmaceutical compositions including  $\beta$ -L-2'-deoxy-3'-substituted cytidines in combination with pharmaceutically acceptable carriers, which find support on page 47, line 20 to page 50, line 15.

The Examiner has restricted the prosecution of the present application to one of three groups of claims. Group I consists of claims 1-155, drawn to 3'- $\beta$ -L-nucleoside compounds and analogs. Group II consists of claims 156, 157, 163 and 164, drawn to 3'-substituted pyrimidine nucleoside compounds. Group III consists of claims 165-174, drawn to methods to treat HBV in a host with a compound of Group I.

Applicants have elected claims 156 and 163 and new claims 192-241 directed to 3'-substituted pyrimidine nucleoside compounds as defined in Group II. This election is made without traverse.

Respectfully submitted,



Sherry M. Knowles, Esq.  
Registration No. 33,052

Date: August 16, 2002

King & Spalding  
191 Peachtree Street  
Atlanta, Georgia 30303  
Telephone: 404-572-3541  
Facsimile: 404-572-5145